There are 2949 resources available
606P - Novel miRNA-based assay for GEP-NENs management
Presenter: Martine Bocchini
Session: E-Poster Display
Resources:
Abstract
607P - Prognostic value of early total, free and bound to lipoprotein fractions plasma mitotane measurements in advanced adrenocortical carcinoma at the time of mitotane initiation: A prospective study of the ENDOCAN-COMETE-cancer network
Presenter: Annabelle Naman
Session: E-Poster Display
Resources:
Abstract
608P - METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours
Presenter: Joao Glasberg
Session: E-Poster Display
Resources:
Abstract
619P - Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network
Presenter: Alfredo Berruti
Session: E-Poster Display
Resources:
Abstract
620P - Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
Presenter: Emanuela Romano
Session: E-Poster Display
Resources:
Abstract
621P - Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
Presenter: Jose Arranz Arija
Session: E-Poster Display
Resources:
Abstract
622P - Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study
Presenter: Neeraj Agarwal
Session: E-Poster Display
Resources:
Abstract
623P - KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
Presenter: Aurelius Omlin
Session: E-Poster Display
Resources:
Abstract
624P - Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
Presenter: Guilhem Roubaud
Session: E-Poster Display
Resources:
Abstract
625P - Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
Presenter: Loic Mourey
Session: E-Poster Display
Resources:
Abstract